Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract
contains data from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present
data from all 114 patients with a more recent data cut off and will be the subject of a further announcement
from the Company.
Ciò che 2 anni fa era un miraggio oggi inizia a prendere forma concreta, ci vorrà ancora qualche anno per avere un farmaco approvato, credo 2025, ma il pps salirà ben prima
Adesso il 3 capiremo meglio, se posso posterò, un caro saluto a tutti e grazie sempre ad Andrea
Immutep Limited's TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer clinical trial conducted in collaboration with MSD. The new data was presented to a packed hall in an Oral Presentation at #ASCO22 by Dr Enriqueta Felip.
The combination of efti plus pembrolizumab shows favourable anti-tumour activity with an Overall Response Rate by local read of 38.6%.
Encouraging responses were observed in all PD-L1 status groups, including those patients with PD-L1 negative and PD-L1 low expressing tumours who are less likely to respond to anti-PD-1 monotherapy.
#LCSM #Immune2Cancer #immunotherapy
ora sentiamo il webcast ma direi che prossimamente novità positive potrebbero arrivare
vediamo come se la gioca il management...
In Australia un bel -5,81%